LY2875358 is an investigational drug designed to inhibit cancer growth by blocking the activity of a protein called MET, which some cancer cells need to grow. Ramucirumab is an anticancer drug approved to treat cancer of the stomach and cancer of the junction between the esophagus and the stomach. It inhibits the growth of the blood vessels that tumors need to grow and spread by blocking the activity of a protein called VEGFR2.
In this study, researchers want to find the highest dose of LY2875358 that can be given safely with ramucirumab in patients with advanced solid cancers that are no longer responding to standard treatments. Both drugs are given intravenously (by vein).